Brain Natriuretic Peptide and Atrial Natriuretic Peptide Levels in Normal Pregnancy and Preeclampsia

Furuhashi, N; Kimura, Hiroyuki; Nagae, H.; Yajima, Akira; Kimura, Chiharu; Saito, Takachika

doi:10.1159/000292452

Cited by 44 publications

(30 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An early study failed to find any association between clinical severity of eclampsia and BNP levels. 37 In Western societies, the most prevalent causes of ventricular impairment are hypertension and coronary artery disease. The level of BNP may reflect both the aetiology and the consequences of hypertension.…”

Section: Prognosis and Screeningmentioning

confidence: 99%

Utility of Brain Natriuretic Peptide (BNP) Measurement in Cardiovascular Disease

Sullivan

West

Jeremy

2005

Heart, Lung and Circulation

View full text Add to dashboard Cite

Section: Prognosis and Screeningmentioning

confidence: 99%

Utility of Brain Natriuretic Peptide (BNP) Measurement in Cardiovascular Disease

Sullivan

West

Jeremy

2005

Heart, Lung and Circulation

View full text Add to dashboard Cite

“…These results, which are summarized in Table 3, suggest that pregnancy reduces the size of V when expressed per kg of body weight, which is the most appropriate comparison, and that V is even lower in PE. Pregnancy decreases the diuretic response to crystalloid volume loading, but this adaptation seems to be abolished by PE, perhaps due to the increased release of atrial natriuretic peptide [2,23]. Moreover, PE doubles the clearance constant for distribution of fluid.…”

Section: Kinetic Parametermentioning

confidence: 99%

Distribution and elimination of crystalloid fluid in pre-eclampsia

Drobin

Hahn

2004

Clinical Science

View full text Add to dashboard Cite

Pre-eclampsia (PE) is a disease of pregnancy associated with peripheral oedema and hypovolaemia, but few details are known about how women with PE handle a volume load of crystalloid fluid compared with healthy pregnant women. To study this issue, Ringer's acetate solution (12.5 ml/kg of body weight) was given by intravenous infusion over 30 min to eight women with PE and to eight healthy pregnant women matched with respect to gestational week (mean, 34 weeks). Venous blood was sampled and excreted urine was collected over 90 min to study the time course of the volume expansion by means of volume kinetic analysis. The results show that the size of the central body fluid space expanded by the infused fluid was smaller in PE (mean, 2940 ml compared with 4240 ml respectively; P<0.04), and the clearance constants for distribution (100 ml/min compared with 43 ml/min; P<0.04) and elimination (125 ml/min compared with 36 ml/min; P<0.02) were higher in the women with PE than in the controls. Less excess volume accumulated in the central body fluid space in the presence of PE, whereas the rates of distribution and elimination were higher during and for 15 min after the infusion. It is concluded that Ringer's acetate solution fluid is both distributed and eliminated faster in women with PE than in matched pregnant controls.

show abstract

“…The initial hope of introducing CDD/ANP-99-126 as a drug for the treatment of acute renal failure (Heidbreter et al 1986;Nakamoto et al 1987;Conger et al 1991;Shaw et al 1992;Rahman et al 1994;Allgren et al 1997) was upset by the negative result of a phase III study (Scios Nova press release, unpublished). A great number of papers show the diagnostic value of natriuretic peptides in several syndromes (Arendt et al 1986;Hollister and Inagami 1991;Lerman et al 1993;Mathisen et al 1993;Buckley et al 1994;Furuhashi et al 1994;Kettunen et al 1994;Richards 1994;Yasue et al 1994;Dickstein et al 1995;Arad et al 1996;Darbar et al 1996;Holmstrom et al 1996;Lohmeier et al 1996;. To date, successful applications of natriuretic peptides are limited to, for example, the use of BNP in heart failure (Hobbs et al 1996;.…”

Section: Pharmacological Actions Of Urodilatin In Preclinical Studiesmentioning

confidence: 99%

The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system

Forssmann

Richter

Meyer

1998

Histochemistry and Cell Biology

View full text Add to dashboard Cite

This review focuses on some selected aspects of the endocrine heart and natriuretic peptides. The endocrine heart is composed of specific myoendocrine cells of the cardiac atria. The myoendocrine cells synthesize and secrete the natriuretic peptide hormones which exhibit natriuretic, diuretic, and vasorelaxant properties. Immunohistochemical analyses show that natriuretic peptides of the A-type and B-type are localized not only in the specific granules of these myoendocrine cells but also in many other organs including the brain, adrenal medulla, and kidney. Also, their receptors are detected in many organs showing the multiple functions of these regulatory peptides. Of the members of the natriuretic peptide family, ANP (ANP for atrial natriuretic peptide; also denominated cardiodilatin, CDD), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and the A-type, including its renal form, urodilatin, are emphasized in this review. Urodilatin is localized in the kidney, differentially processed, and secreted into the urine. The intrarenal synthesis and secretion is the basis for a paracrine system regulating water and sodium reabsorption at the level of the collecting duct. CDD/ANP-1-126, cleaved from a precursor of 126 amino acids in the heart to a 28-amino acid-containing circulating molecular form (CDD/ANP-99-126), and urodilatin (CDD/ANP-95-126) share similar biochemical features and biological functions, but urodilatin may be more involved in the regulation of body fluid volume and water-electrolyte excretion, while circulating CDD/ANP-99-126 is responsible for blood pressure regulation. The physiological and pharmacological properties of these peptides have great clinical impact, and as a consequence urodilatin is involved in drug development for the treatment of acute renal failure, cardiomyopathia, and acute asthma.

show abstract

Brain Natriuretic Peptide and Atrial Natriuretic Peptide Levels in Normal Pregnancy and Preeclampsia

Cited by 44 publications

References 12 publications

Utility of Brain Natriuretic Peptide (BNP) Measurement in Cardiovascular Disease

Utility of Brain Natriuretic Peptide (BNP) Measurement in Cardiovascular Disease

Distribution and elimination of crystalloid fluid in pre-eclampsia

The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system

Contact Info

Product

Resources

About